吸收不良症候群市场规模、份额和成长分析：按病因、按诊断工具、按治疗方法、按最终用户、按地区 - 行业预测，2024-2031 年

吸收不良症候群市场规模在 2022 年为 22.9 亿美元，从 2023 年的 24.3 亿美元成长到 2031 年的 39.4 亿美元，预测期间（2024-2031 年）预计将以 6.2% 的复合年增长率增长。

吸收不良症候群包括多种以胃肠道营养吸收受损为特征的疾病，例如乳糜泻、克隆氏症和其他胃肠道疾病。由于生活方式的改变、饮食和人口老化，全球吸收不良症候群市场的盛行率不断增加，推动了对诊断工具和治疗方案的需求。诊断技术的进步，例如改进的成像、生物标记的识别和基因检测，大大提高了吸收不良综合征诊断的速度和准确性，从而可以及时进行医疗干预。此外，患者和医疗保健提供者意识的提高也促进了早期发现和管理。教育工作和资讯传播使人们能够识别症状并接受适当的医疗护理，从而改善结果。

目录

介绍

• 这项研究的目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

吸收不良症候群市场洞察

• 市场生态系统
• 监管环境
• 创新矩阵
• 主要投资分析
• 关键成功因素
• 市场魅力指数
• 竞争程度

吸收不良症候群市场：依病因分类

• 市场概况
• 乳糜泻
• 肠道疾病
• 惠普尔氏症
• 短肠症候群
• 其他的

吸收不良症候群市场：依诊断工具分类

• 市场概况
• 影像
  • MRI
  • 电脑断层扫描
• 验血
  • 血清营养水平
  • 基因检测
• 内视镜检查
• 切片检查

吸收不良症候群市场：治疗方法

• 市场概况
• 药品
  • 补充酶
  • 发炎药
• 膳食食品
  • 维他命
  • 矿物
• 改善饮食习惯
• 手术治疗

吸收不良症候群市场：依最终用户分类

• 市场概况
• 医院药房
• 营养诊所
• 学术研究所
• 其他的

吸收不良症候群市场：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• AbbVie Inc.（United States）
• Allergan plc（Ireland）
• Bausch Health Companies Inc.（Canada）
• Bayer AG（Germany）
• Dr. Reddy's Laboratories Ltd.（India）
• GlaxoSmithKline plc（United Kingdom）
• Johnson & Johnson（United States）
• Merck & Co., Inc.（United States）
• Mylan NV（Netherlands）
• Novartis AG（Switzerland）
• Pfizer Inc.（United States）
• Roche Holding AG（Switzerland）
• Sanofi SA（France）
• Takeda Pharmaceutical Company Limited（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• AstraZeneca PLC（United Kingdom）
• Eisai Co., Ltd.（Japan）
• Ferring Pharmaceuticals（Switzerland）
• Mallinckrodt Pharmaceuticals（United Kingdom）
• UCB SA（Belgium）

Malabsorption Syndrome Market size was valued at USD 2.29 billion in 2022 and is poised to grow from USD 2.43 billion in 2023 to USD 3.94 billion by 2031, growing at a CAGR of 6.2% during the forecast period (2024-2031).

Malabsorption Syndrome encompasses a range of conditions characterized by impaired nutrient absorption in the gastrointestinal tract, stemming from factors like celiac disease, Crohn's disease, and other gastrointestinal disorders. The global market for Malabsorption Syndrome has seen increased prevalence due to lifestyle changes, dietary habits, and an aging population, driving demand for diagnostic tools and treatment options. Advances in diagnostic technologies, including improved imaging modalities, biomarker identification, and genetic testing, have significantly enhanced the speed and accuracy of Malabsorption Syndrome diagnosis, enabling timely medical interventions. Moreover, heightened awareness among patients and healthcare providers has facilitated early detection and management. Education initiatives and information dissemination have empowered individuals to recognize symptoms and seek appropriate medical care, resulting in improved outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Malabsorption Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Malabsorption Syndrome Market Segmental Analysis

The global Malabsorption Syndrome market is segmented based on Causative Diseases, Diagnostic Tools, Treatment Modalities, End-User, and region. Based on Causative Diseases, the market is segmented into Celiac Disease, Crohn's Ailment, Intestinal Disorders, Whipple's Disease, Short Bowel Syndrome, and Others. Based on Diagnostic Tools, the market is segmented into Imaging (MRI, CT scans), Blood Tests (Serum nutrient levels, Genetic testing), Endoscopy & Biopsy. By treatment modalities, the market is segmented into Medications (Enzyme replacement, Anti-inflammatory drugs), Nutritional Supplements (Vitamins, Minerals), Diet Modification, Surgical Interventions. By End-User type, the market is segmented into Hospital Pharmacy, Nutrition Clinics, Academic & Research Institutes, others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

Drivers of the Malabsorption Syndrome Market

Increasing incidence of malabsorption disorders, driven by factors such as evolving lifestyles, dietary patterns, and an aging population, has significantly increased the need for diagnostic and treatment solutions. Advances in diagnostic technology and heightened awareness among healthcare providers and patients have enabled early detection and intervention, positively influencing market growth.

Restraints in the Malabsorption Syndrome Market

One of the primary challenges in the market is the intricate and varied nature of malabsorption disorders, which presents difficulties in accurate diagnosis and tailored treatment. Economic factors, reimbursement challenges, and disparities in healthcare infrastructure across different regions can create obstacles to optimal patient care. Moreover, the high costs associated with advanced diagnostic technologies and specialized treatments may limit accessibility for certain populations, thereby impeding widespread adoption.

Market Trends of the Malabsorption Syndrome Market

There is an increasing focus on personalized medicine, emphasizing the customization of diagnostic and treatment approaches according to individual patient characteristics. This trend aligns with advancements in genetic testing and biomarker identification, enabling more precise and targeted interventions. Additionally, there is a notable movement towards the development of innovative therapeutic approaches, including biologics and gene therapies, demonstrating a continuous commitment to addressing the various causes of malabsorption disorders.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Malabsorption Syndrome Market Insights

• Ecosystem of the Market
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Malabsorption Syndrome Market by Causative Diseases

• Market Overview
• Celiac Disease
• Intestinal Disorders
• Whipple's Disease
• Short Bowel Syndrome
• Others

Malabsorption Syndrome Market by Diagnostic Tools

• Market Overview
• Imaging
  • MRI
  • CT scans
• Blood Tests
  • Serum nutrient levels
  • Genetic testing
• Endoscopy
• Biopsy

Malabsorption Syndrome Market by Treatment Modalities

• Market Overview
• Medications
  • Enzyme replacement
  • Anti-inflammatory drugs
• Nutritional Supplements
  • Vitamins
  • Minerals
• Diet Modification
• Surgical Interventions

Malabsorption Syndrome Market by End-User

• Market Overview
• Hospital Pharmacy
• Nutrition Clinics
• Academic & Research Institutes
• Others

Malabsorption Syndrome Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments